A subtle change in brain wave activity could predict Alzheimer's disease more than two years before diagnosis, according to a ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals ...

How can we influence whether we develop Alzheimer's disease later in life? Neurodegeneration researchers at the Institute for ...

Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment.

A research group led by Professor Michael Glickman, dean of Technion's Faculty of Biology, has uncovered a key mechanism in ...

A breakthrough new Alzheimer’s disease treatment is stopping neurodegeneration in its tracks, even before symptoms appear. The experimental drug, called NU-9, has been showing these radical results in ...

Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...

A new drug candidate shows promise by reversing cognitive decline in advanced Alzheimer's disease by restoring brain balance ...

Discovery could redirect drug development for disease affecting 6.7 million Americans The two AMPKα isoforms can have ...

Dr Pritchard explains: “Diabetes damages the blood vessels within the brain, making them leakier and reducing the amount of ...

Some people are immune to dementia, even if their brain is deteriorating. Cognitive reserve is the secret boost that builds ...